Indeed, DS-6051b but not entrectinib or lorlatinib suppressed tumor growth of the G2032R mutant models (Ba/F3-CD74-ROS1-G2032R and HCC78xe3-SLC34A2-ROS1-G2032R) in vivo. Here, ROS1 is linked to neoplasm.